Loyal Fully Enrolls LOY-002 Dog Lifespan Pilot Study

The LOY-002 clinical pilot study by Loyal has been fully enrolled with 60 older dogs to test a daily tablet aimed at extending their lifespan and quality of life.

The pilot study is a precursor to a larger pivotal study intended to prove safety and effectiveness to the FDA, and is one of the largest veterinary clinical trials ever attempted.

The study hit enrollment goals on time, proving operational viability for the upcoming FDA-reviewed pivotal study for LOY-002.

Loyal's clinical team, strong site partnerships, and dog owner engagement were key to enrollment success, with ongoing recruitment for future trials.

The study involves first-time clinical dosing of LOY-002 and will analyze its impact on aging-related biomarkers.